Universal Ibogaine (TSXV:IBO) FCF Margin % : -54.30% (As of Jan. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Universal Ibogaine FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Universal Ibogaine's Free Cash Flow for the three months ended in Jan. 2025 was C$-0.20 Mil. Universal Ibogaine's Revenue for the three months ended in Jan. 2025 was C$0.37 Mil. Therefore, Universal Ibogaine's FCF Margin % for the quarter that ended in Jan. 2025 was -54.30%.

As of today, Universal Ibogaine's current FCF Yield % is -13.92%.

The historical rank and industry rank for Universal Ibogaine's FCF Margin % or its related term are showing as below:

TSXV:IBO' s FCF Margin % Range Over the Past 10 Years
Min: -413.54 Med: -141.46 Max: -39.38
Current: -56.62

During the past 8 years, the highest FCF Margin % of Universal Ibogaine was -39.38%. The lowest was -413.54%. And the median was -141.46%.

TSXV:IBO's FCF Margin % is ranked better than
58.16% of 999 companies
in the Biotechnology industry
Industry Median: -121.51 vs TSXV:IBO: -56.62

Universal Ibogaine FCF Margin % Historical Data

The historical data trend for Universal Ibogaine's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Ibogaine FCF Margin % Chart

Universal Ibogaine Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Jul22

Jul23

Jul24

FCF Margin %

Get a 7-Day Free Trial

-413.54

-141.46

-39.38

Universal Ibogaine Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
FCF Margin %	Get a 7-Day Free Trial															-13.07	-96.83	-18.78	-57.58	-54.30

Competitive Comparison of Universal Ibogaine's FCF Margin %

For the Biotechnology subindustry, Universal Ibogaine's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universal Ibogaine's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Universal Ibogaine FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Universal Ibogaine's FCF Margin for the fiscal year that ended in Jul. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Jul. 2024 )	/	Revenue (A: Jul. 2024 )
	=	-0.918	/	2.331
	=	-39.38 %

Universal Ibogaine's FCF Margin for the quarter that ended in Jan. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jan. 2025 )	/	Revenue (Q: Jan. 2025 )
	=	-0.202	/	0.372
	=	-54.30 %

Universal Ibogaine FCF Margin % Related Terms

Thank you for viewing the detailed overview of Universal Ibogaine's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Universal Ibogaine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Universal Ibogaine Inc (TSXV:IBO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

IBOGF:USA JC4:Germany

Address

C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2

Website

https://www.universalibogaine.com

Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.

Executives

Ian Rabb

Senior Officer

Universal Ibogaine Headlines

From GuruFocus

DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value

By Marketwired • 09-16-2024